Loading organizations...
Loading organizations...
Hope Medicine is a technology company.
Hope Medicine has raised $102.0M across 3 funding rounds.
Hope Medicine has raised $102.0M in total across 3 funding rounds.
Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations.
Hope Medicine has raised $102.0M in total across 3 funding rounds.
Hope Medicine's investors include Illumina Ventures, Qiming Venture Partners, VMS Group, Sinovation Ventures, Trustbridge Partners, Xiaolong Yang, Feng Ge.
Hope Medicine (HopeMed) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine, cardiovascular, metabolic diseases, and women's health, targeting underserved patient populations with safe, effective, and affordable medicines.[1][2][5] Its lead candidate, HMI-115—a monoclonal antibody targeting the prolactin receptor—received U.S. FDA Fast Track Designation in December 2025 for moderate to severe endometriosis pain, following Phase II results showing 42% reduction in dysmenorrhea pain and 52% in chronic pelvic pain, with most patients maintaining normal cycles and no major safety issues.[2] Founded in 2018 with labs in Beijing, Shanghai, and Nanjing, HopeMed serves patients with high unmet needs in a ~$200 billion endometriosis market alone, demonstrating growth via funding rounds like a $56M Series B in 2021 and pre-IPO share trading interest.[4]
Hope Medicine emerged from decades of research in Professor Rui-Ping Xiao's laboratory at Peking University's Institute of Molecular Medicine, leveraging her expertise in disease biology and translational medicine.[1][2] Established in 2018, the company was co-founded by scientific leaders and industry veterans, including CEO Henri Nico Doods and Co-founder/President/COO Sam Lou, blending academic rigor with global pharma experience.[1][4] Early traction built on internal R&D in endocrinology and metabolism, expanding via in-licensing and external platforms; pivotal moments include Phase II success for HMI-115 and FDA Fast Track in 2025, alongside funding like the 2021 Series B and 2024 mentions of additional raises.[2][4]
Hope Medicine rides the wave of precision biotech in women's health and metabolic disorders, addressing gaps in endometriosis treatments amid a $200B global market with few non-hormonal, fertility-preserving options.[2] Timing aligns with rising FDA support for innovative modalities like prolactin receptor antagonists, fueled by China's biotech boom—evident in its funding and Phase II successes—countering historical Western dominance.[1][4] Market forces like aging populations, infertility epidemics, and demand for affordable therapies favor its China-based efficiency; it influences the ecosystem by validating translational research from academia (Peking University) into clinical wins, inspiring similar hubs and accelerating non-hormonal alternatives.[2][5]
Hope Medicine's FDA Fast Track positions HMI-115 for potential Phase III trials and global approval by late 2020s, expanding its pipeline into commercialization for endometriosis and beyond.[2] Trends like AI-enabled discovery, women's health investment surges, and China-U.S. biotech bridges will propel growth, with pre-IPO liquidity signaling scalability.[4] Its influence may evolve from niche innovator to pipeline leader in metabolic/women's health, delivering first-in-class impact for underserved patients—echoing its founding promise of science-driven hope.
Hope Medicine has raised $102.0M across 3 funding rounds. Most recently, it raised $18.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $18.0M Series B | Illumina Ventures, Qiming Venture Partners | |
| Feb 1, 2024 | $28.0M Series B | VMS Group | Illumina Ventures, Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners |
| May 1, 2021 | $56.0M Series B | Qiming Venture Partners | Illumina Ventures, Xiaolong Yang, Feng Ge |